WallStSmart

Edwards Lifesciences Corp (EW)vsFomento Economico Mexicano (FMX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fomento Economico Mexicano generates 13431% more annual revenue ($852.92B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 3.3%. EW appears more attractively valued with a PEG of 2.04. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9

FMX

Buy

54

out of 100

Grade: C-

Growth: 6.0Profit: 5.5Value: 4.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.26
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.7%)

Margin of Safety

+69.7%

Fair Value

$261.90

Current Price

$79.96

$181.94 discount

UndervaluedFair: $261.90Overvalued

Intrinsic value data unavailable for FMX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

FMX2 strengths · Avg: 9.0/10
EPS GrowthGrowth
167.8%10/10

Earnings expanding 167.8% YoY

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

FMX4 concerns · Avg: 3.0/10
P/E RatioValuation
26.2x4/10

Moderate valuation

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
6.942/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : FMX

The strongest argument for FMX centers on EPS Growth, Price/Book.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.

Bear Case : FMX

The primary concerns for FMX are P/E Ratio, Profit Margin, Piotroski F-Score. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

EW profiles as a growth stock while FMX is a value play — different risk/reward profiles.

EW carries more volatility with a beta of 0.87 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

FMX generates stronger free cash flow (842M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 54/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Fomento Economico Mexicano

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Fomento Econmico Mexicano, SAB de CV, is a bottler of Coca-Cola brand beverages. The company is headquartered in Monterrey, Mexico.

Want to dig deeper into these stocks?